SCHEMBL14973140

SCHEMBL14973140

Cn1ncc(C(=O)O)c1CCc1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
PTPN1 P18031 3/20 0.40
NR4A3 Q92570 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 2/20 0.40
BRS3 P32247 1/20 0.40
ALDH1A1 P00352 2/20 0.39
HTT P42858 2/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
P2RX7 Q99572 1/20 0.39
BRD4 O60885 1/20 0.39
KAT2B Q92831 1/20 0.39
MITF O75030 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
KDM5A P29375 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14973078 0.85 PTPN1 (0.44) PTPN1NR4A3P2RX7KEAP1NFE2L2
SCHEMBL14973035 0.85 ASPH (0.42) SMN1; SMN2NR4A3KDM4E
SCHEMBL14973205 0.83 ALDH1A1 (0.47) SMN1; SMN2CYP1A2CYP2C19KMT2AKDM4E
SCHEMBL14938084 0.76 BRD4 (0.39) SMN1; SMN2ALDH1A1BRD4KAT2B
SCHEMBL16256558 0.75 NR4A3 (0.45) SMN1; SMN2NR4A3KMT2AKDM4EALDH1A1
SCHEMBL30322820 0.75 NR4A3 (0.40) SMN1; SMN2NR4A3KDM4EALDH1A1P2RX7
SCHEMBL14973107 0.73 KDM4E (0.43) SMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL4757065 0.73 NR4A3 (0.58) SMN1; SMN2NR4A3KDM4EALDH1A1KDM5A
SCHEMBL15750778 0.73 KDM4E (0.54) KDM4ERAB9AKDM5AKDM5B
SCHEMBL22534352 0.73 NR4A3 (0.51) PTPN1NR4A3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A SMN1; SMN2 3612/4885PTPN1 2140/4885NR4A3 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.